Description:
The risk factors affecting chemotherapy-induced nausea and vomiting (CINV) includes antiemetic premedication time pattern, and this study investigates the capability of enhancing this in breast cancer patients receiving high emetogenic chemotherapy (HEC). Furthermore, this observational research was implemented at the oncology unit of Dr. Soetomo General Hospital Surabaya over a three-month period involving 69 female patients. The results showed unspecifc antiemetic premedication timing in comparison to those with recommended timeframes, was connected with greater occurrence of both acute nausea in all cycles of chemotherapy (p<0.05), and acute vomiting in second and third cycles (p<0.05) but not in the frst cycle (p=0.49). However, specifc time administration of antiemetic treatment was linked with lower incidence of delayed nausea in all cycles (p<0.05), and less delayed vomiting in second and third cycles (p<0.05) but not in frst cycle (p=0.10). These fndings indicate specifc time administration of antiemetic drugs causes signifcant advantages in mitigating CINV among breast cancer patients treated with emetogenic chemotherapy, and signifcantly lessened the occurrence of acute and delayed nausea and vomiting.

URL:
http://103.158.96.210:88/web_repository/uploads/26768-105926-1-PB.pdf

Type:
Journal

Document:
Diploma III Farmasi

Date:
23-06-2024

Author:
Mahardian Rahmadi